Pretty ordinary result from my perspective, with a fair bit of quibbling on ins and outs.
No evidence for an impact from the RCT results, but really shouldn't expect it over such a short timeframe. The US ECP numbers are still flat, and the revenue per ECP (a simple average) is shown up to be the uninformative measure it is - much better to be given the median revenue per ECP, so one could see the growth of the bulk of ECP businesses as they mature in their myopia management.
Latest research report from Jobson (461 US ECPs surveyed) shows the challenge in front of VTI.
First, ECPs rely first and foremost on FDA approval - off-label prescribing is a key limitation for them:
Second, and surprisingly, Parents don't really care about FDA approval - it is cost they are focussed on:
So, ECPs are focussing on FDA approval, while parents are focussing on cost. Changing the ECPs perception is the challenge VTI has using the 1-yr RCT results.
If we can do this, we should do well as we can compete on both on the direct price of the product, and the indirect cost to ECPs (less chair time to fit)
